Boston Partners Sells 56,581 Shares of Enovis Co. (NYSE:ENOV)

Boston Partners lessened its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 36.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 96,558 shares of the company's stock after selling 56,581 shares during the period. Boston Partners owned about 0.18% of Enovis worth $5,410,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Enovis by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company's stock valued at $258,242,000 after buying an additional 51,319 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Enovis by 3.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,193,699 shares of the company's stock valued at $178,912,000 after buying an additional 117,209 shares in the last quarter. Diamond Hill Capital Management Inc. grew its holdings in Enovis by 9.9% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company's stock valued at $128,090,000 after buying an additional 219,659 shares in the last quarter. DAVENPORT & Co LLC grew its holdings in Enovis by 12.6% during the 4th quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company's stock valued at $105,920,000 after buying an additional 210,358 shares in the last quarter. Finally, Channing Capital Management LLC grew its holdings in Enovis by 26.6% during the 4th quarter. Channing Capital Management LLC now owns 1,588,417 shares of the company's stock valued at $88,983,000 after buying an additional 334,154 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Stock Performance

Shares of Enovis stock traded up $0.21 on Friday, reaching $52.41. 335,780 shares of the stock were exchanged, compared to its average volume of 492,802. The company has a quick ratio of 1.03, a current ratio of 2.10 and a debt-to-equity ratio of 0.40. Enovis Co. has a twelve month low of $43.04 and a twelve month high of $66.14. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -34.94 and a beta of 1.99. The business has a 50 day moving average price of $57.18 and a two-hundred day moving average price of $56.12.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 2nd. The company reported $0.50 EPS for the quarter, hitting analysts' consensus estimates of $0.50. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The firm had revenue of $516.00 million during the quarter, compared to the consensus estimate of $505.62 million. During the same quarter in the previous year, the company posted $0.44 earnings per share. The company's revenue was up 27.0% compared to the same quarter last year. Analysts anticipate that Enovis Co. will post 2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Stephens initiated coverage on shares of Enovis in a report on Tuesday, February 13th. They set an "overweight" rating and a $72.00 price objective for the company. Wells Fargo & Company increased their target price on Enovis from $73.00 to $79.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Canaccord Genuity Group increased their target price on Enovis from $73.00 to $75.00 and gave the company a "buy" rating in a research report on Friday, February 23rd. Needham & Company LLC reiterated a "buy" rating and set a $82.00 target price on shares of Enovis in a research report on Friday, May 3rd. Finally, UBS Group initiated coverage on Enovis in a research report on Monday, January 22nd. They set a "buy" rating and a $75.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $75.43.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.